Tradestie Institutional Equity Comparison Engine

CVAC vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CVAC Overall Edge

CVAC Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CureVac N.V. Ordinary Shares (CVAC) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CVAC trades at 5.2x Forward P/E with 573.0% operating margin (-89.0% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, CVAC sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVAC
CVAC 5.2x vs BHST N/M Fwd P/E
Growth & Margin Winner CVAC
Op Margin 573.0% vs -18.0% ยท YoY -89.0% vs +3.8%
Momentum & Technical Winner CVAC
1Y +36.7% vs -79.4% ยท 52W Pos 67% vs 6%
Options & Structure Winner CVAC
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
CVAC NASDAQ
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap $1.1B
1M Return -9.95%
1Y Return +36.66%
Forward P/E 5.2x
Unified AI Score
60.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 58.9
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVAC +36.66% BHST -79.4% Spread: +3.53 pp (CVAC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CVAC TTM Op. Margin: 573.0% BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVAC vs BHST. Trailing 12-month operating profitability (CVAC 573.0% vs BHST -18.0%) and valuation multiples (CVAC 5.2x vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVAC (9) vs BHST (1)
Institutional Metric CVAC BHST Criterion Row Winner
Market Capitalization Scale $1.1B $29.9M Larger Scale CVAC
Trailing P/E Ratio Valuation 7.0x N/M Lower Multiple CVAC
Forward P/E Ratio Valuation 5.2x N/M Lower Multiple CVAC
Revenue Growth (YoY) Growth -89.0% +3.8% Higher Growth BHST
Operating Margin (TTM) Profitability 573.0% -18.0% Higher Margin CVAC
Net Profit Margin Profitability 182.1% -31.2% Higher Margin CVAC
Return on Equity (ROE) Capital Efficiency 40.2% -142.5% Higher ROE CVAC
52-Week Range Position Momentum 67% ($2โ€“$6) 6% ($1โ€“$7) Stronger Trend CVAC
Beta / 30D Volatility Risk Regime 1.20ฮฒ ยท 62% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk CVAC
Unified Institutional Score Composite Signal 60.2 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite CVAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVAC vs BHST Buy Guide
CVAC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CVAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVAC nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.